Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: a case report

Exp Hematol. 2013 Jun;41(6):505-7. doi: 10.1016/j.exphem.2013.02.011. Epub 2013 Feb 24.

Authors

Ramy Rahmé¹, Emmanuel Benayoun, Cécile Pautas, Catherine Cordonnier, Orianne Wagner-Ballon, Sébastien Maury

Affiliation

¹ Department of Hematology, Henri Mondor University Hospital, Créteil, France.

PMID: 23462143
DOI: 10.1016/j.exphem.2013.02.011

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antigens, CD20 / biosynthesis*
Antigens, CD20 / genetics
Antimetabolites, Antineoplastic / administration & dosage
Antimetabolites, Antineoplastic / pharmacology*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Azacitidine / administration & dosage
Azacitidine / pharmacology*
Combined Modality Therapy
DNA (Cytosine-5-)-Methyltransferase 1
DNA (Cytosine-5-)-Methyltransferases / antagonists & inhibitors
Enzyme Inhibitors / pharmacology
Fatal Outcome
Female
Gene Expression Regulation, Leukemic / drug effects*
Hematopoietic Stem Cell Transplantation
Histone Deacetylase Inhibitors / administration & dosage
Humans
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
Recurrence
Rituximab
Salvage Therapy
Transplantation, Homologous
Up-Regulation / drug effects
Valproic Acid / administration & dosage

Substances

Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Antimetabolites, Antineoplastic
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Rituximab
Valproic Acid
DNA (Cytosine-5-)-Methyltransferase 1
DNA (Cytosine-5-)-Methyltransferases
Azacitidine